#NEWS There is an imperative need to address the barriers around perception and gaps in care for mental health conditions, such as schizophrenia. Find out more in this new report from Economist Impact on how to ensure better care for every mind:

#NEWS : We are excited to expand our partnership with OSE Immunotherapeutics - Biotechs & immunothérapie to develop novel first-in-class treatments for cancer and cardio-renal-metabolic (CRM) diseases.

Learn more: bit.ly/3V9fWmn

#CardioMetabolic #Cancer #ResearchAndDevelopment

#NEWS : We're excited to share our positive data from the Phase I/IIa HORNBILL study in diabetic macular ischema (DMI).
#RetinalHealth #ARVO2024

Learn more 👉 bit.ly/3JUk5nD

#NEWS : Announcing our new partnership with Ochre Bio to develop novel regenerative treatments for patients with advanced liver disease, including metabolic associated steatohepatitis ( #MASH ) cirrhosis.

Learn more: bit.ly/4d5DYpk

#LiverDisease #ResearchAndDevelopment

#PRESS : In 2023
👉 we invested EUR 5.8 bn in #innovation
👉 helped more than 61 mln patients

Our ≈ 53,500 employees keep working on breakthrough solutions that improve lives of humans & animals in a sustainable way. But there’s more! Check it out ➡️ bit.ly/4aOFDNW

#Journalists : At our Annual #Press Conference on April 16, we'll discuss our performance and major milestones achieved in 2023 and provide an outlook for 2024 and beyond. Register now ➡️ bit.ly/3vrA8G9

#NEWS : U.S. FDA and the Chinese National Medical Products Administration (NMPA) approved our generalized pustular psoriasis ( #GPP ) treatment option for expanded indications. GPP is a chronic inflammatory disease, greatly impacting quality of life. ➡️ bit.ly/3ToXCnb

#NEWS : We are expanding our mental health pipeline by partnering with @soseiheptaresco in an effort to further develop novel, first-in-class treatments for schizophrenia.

Learn more: bit.ly/3PhlUhM

#Schizophrenia #MentalHealth #ResearchAndDevelopment

#NEWS : We’re excited to share that our Phase II trial in adults with metabolic dysfunction-associated steatohepatitis (MASH) & liver fibrosis stages F1, F2 & F3 met its primary endpoint & all key secondary endpoints. #LifeForward
Learn more 👉 bit.ly/3Ibj5e8

#NEWS : We are joining forces with CBmed to make the development of transformational new medicines faster and more accurate for people living with cancer.

Learn more: bit.ly/3HR9yZv

#ResearchCollaboration #Cancer #TranslationalMedicine

#NEWS : We will invest EUR 120 million to further upgrade our plant in Koropi, Greece, with new technologies to increase its #manufacturing capacity of key strategic medications as well as export capability.
Read more ➡️ bit.ly/4aS0aSz

#NEWS : We have entered into five new R&D partnerships this year already. Looking forward to working with our new partners and to entering into more R&D partnerships in 2024.

Learn more: bit.ly/41SWlbH

#Innovation #ResearchCollaboration

#NEWS : We are starting the ADVANCE study, the most extensive clinical study into liver cirrhosis ever conducted in partnership with researchers at University of Newcastle and Edinburgh University.

Learn more: bit.ly/48PsHql

#NASH #Cirrhosis #ClinicalStudy

#NEWS : We have entered into a license agreement with Kyowa Kirin to develop novel, first-in-class treatments for people living with fibro-inflammatory diseases.

Learn more: bit.ly/4aM5ZkI

#Innovation #Fibrosis

#NEWS : We are continuing our successful collaboration with 3T Biosciences to develop more novel cancer immunotherapies for people living with cancer.

Learn more: bit.ly/3vosSKV

#ImmunoOncology #JPM2024

#NEWS : We are partnering with Ribo Life Science and Ribocure Pharmaceuticals to develop new effective treatments for NASH/MASH - one of the most urgent patient needs.

Learn more: bit.ly/48gOG9J

#NASH #Innovation #LifeForward

#NEWS : Together with Eli Lilly and Company we are happy to share that Jardiance® (empagliflozin) has received approval from the European Commission for the treatment of children aged 10 years and above with #Type2Diabetes , following recent approval by the U.S. FDA 👉 bit.ly/3R8AojZ

#News : Our Venture Fund invests in @Obulytix to develop antimicrobial resistant ( #AMR ) infection treatments. We are committed to invest EUR 200 million to combat emerging infectious diseases.
Learn more: bit.ly/4a6K0Vc

#BacterialInfections #Innovation

#NEWS : We're joining forces with IBM to further drug discovery for unmet patient needs. Our teams will collaborate to develop an unprecedented antibody design platform to accelerate our R&D.
Learn more: bit.ly/3Ritzxv

#ArtificialIntelligence #ResearchAndDevelopment

#NEWS : We are acquiring T3 Pharmaceuticals aiming to cure cancers and transform lives through science. Learn more about how we will realize the full potential of this novel cancer therapy platform: bit.ly/47BJHjm

#ResearchCollaboration #ImmunoOncology #Cancer